Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 151, 96-105
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute (T32HL007055)
This publication has 46 references indexed in Scilit:
- The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort studyBMJ Open, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The Emerging Role of Electronic Medical Records in PharmacogenomicsClinical Pharmacology & Therapeutics, 2011
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-AnalysisDiabetes Care, 2009
- The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational StudiesMedical Decision Making, 2009
- 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review GroupSpine, 2009
- Statins and newly diagnosed diabetesBritish Journal of Clinical Pharmacology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002